

Table 4 Comparison of reports of adverse events following immunization (AEFI) by type of vaccine in developed countries and Oman

| Vaccine | AEFI per 100 000 doses | | | | |
|------------------|------------------------|-------------------|---------------------|------------------------|-------|
| | Oman ^a | Oman ^b | Canada ^c | Australia ^d | |
| | 2006–2015 | 1996–2005 | 2011–2012 | 2012 | 2013 |
| BCG | 37.9 | 69.7 | – | – | – |
| DTP | 11.5 | 15.3 | 20.0 | 57.6e | 75.2e |
| Hib | – | 2.3 | 63.8 | 23.2 | 56.2 |
| Measles | – | 2.9 | – | – | – |
| MMR | 3.6 | 3.6 | 68.2 | 47.8 | 83.6 |
| HBV | 0.6 | 1.5 | 22.0 | – | – |
| Penta | 15.1 | 21.7 | – | – | – |
| Hexa | 0.01 | – | 148.2 | 40.2 | 53.7 |
| PCV ^f | 2.7 | – | – | – | – |
| IPV ^g | 1.6 | – | – | – | – |

Sources: ^aCurrent study, ^b(5), ^c(11), ^d(10).

^eDTPa.

^f2009–2015.

(–) = No study data available.

BCG = bacille Calmette–Guérin, DTP = diphtheria–tetanus–pertussis, Hib = *Haemophilus influenzae* type B, MMR = measles–mumps–rubella, HBV = hepatitis B virus, Penta = DTP–Hib–HBV, Hexa = IPV–DTP–Hib–HBV, PCV = pneumococcal conjugate vaccine, IPV = inactivated polio vaccine.